Items where Author is "Einsele, H."

Article

Hayden, P. J. and Roddie, C. and Bader, P. and Basak, G. W. and Bonig, H. and Bonini, C. and Chabannon, C. and Ciceri, F. and Corbacioglu, S. and Ellard, R. and Sanchez-Guijo, F. and Jaeger, U. and Hildebrandt, M. and Hudecek, M. and Kersten, M. J. and Koehl, U. and Kuball, J. and Mielke, S. and Mohty, M. and Murray, J. and Nagler, A. and Rees, J. and Rioufol, C. and Saccardi, R. and Snowden, J. A. and Styczynski, J. and Subklewe, M. and Thieblemont, C. and Topp, M. and Ispizua, A. U. and Chen, D. and Vrhovac, R. and Gribben, J. G. and Kroeger, N. and Einsele, H. and Yakoub-Agha, I (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). ANNALS OF ONCOLOGY, 33 (3). pp. 259-275. ISSN 0923-7534, 1569-8041

Knop, Stefan and Engelhardt, Monika and Liebisch, Peter and Meisner, Christoph and Holler, Ernst and Metzner, Bernd and Peest, Dietrich and Kaufmann, Martin and Bunjes, Donald and Straka, Christian and Fischer, Thomas and Sezer, Orhan and Hentrich, Marcus and Ostermann, Helmut and Bassermann, Florian and Hess, Georg and Hertenstein, Bernd and Freund, Mathias and Kropff, Martin and Schmidt, Christian A. and Wolf, Hans-Heinrich and Jung, Wolfram and Frickhofen, Norbert and Mielke, Stephan and Bargou, Ralf C. and Maschmeyer, Georg and Svaldi, Mirija and Langer, Christian H. and Gramatzki, Martin and Hebart, Holger and Kanz, Lothar and Einsele, Hermann and Sezer, O. and Doerken, B. and Gerecke, C. and Fuhrmann, S. and Ludwig, W. D. and Hertenstein, B. and Bormann, M. and Meyer, R. and Naumann, R. and Platzbecker, U. and Roellig, Ch and Roesler, W. and von Metzler, I and Martin, H. and Engelhardt, M. and Finke, J. and Truemper, L. and Jung, W. and Schmidt, Ch A. and Doelken, G. and Wolf, H. H. and Mueller, L. and Ligeti, K. and Kroeger, N. and Schilling, G. and Duerk, H. and Peest, D. and Ganser, A. and Pfreundschuh, M. and Sayer, H. and von Lilienfeld-Toal, M. and Muegge, L. O. and Bentz, M. and Gramatzki, M. and Brueggemann, M. and Fischer, T. and Wolleschak, D. and Hess, G. and Kropff, M. and Reusch, J. and Straka, C. and Ostermann, H. and Franke, D. and Peschel, C. and Dechow, T. and Bassermann, F. and Hentrich, M. and Wandt, H. and Schaefer-Eckart, K. and Metzner, B. and Maschmeyer, G. and Holler, E. and Hart, C. and Reichle, A. and Freund, M. and Boettcher, S. and Kahl, C. and Mergenthaler, H. G. and Aulitzky, W. and Kaufmann, M. and Greiner, J. and Heidemann, E. and Kanz, L. and Hebart, H. and Liebisch, P. and Bunjes, D. and Langer, C. and Frickhofen, N. and Einsele, H. and Knop, S. and Mielke, S. and Bargou, R. C. and Svaldi, M. (2019) Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. LEUKEMIA, 33 (11). pp. 2710-2719. ISSN 0887-6924, 1476-5551

Knop, S. and Langer, C. and Engelhardt, M. and Muegge, L.-O. and Reichle, A. and Roesler, W. and Bassermann, F. and Hertenstein, B. and Kunitz, A. and Roellig, C. and Ostermann, H. and Schaefer-Eckart, K. and Ringhoffer, M. and Guenther, A. and Junghanss, C. and Biersack, H. and Schreder, M. and Liebert, A. and Held, S. and Einsele, H. and Bargou, R. C. (2017) Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. LEUKEMIA, 31 (8). pp. 1816-1819. ISSN 0887-6924, 1476-5551

Neuenhahn, M. and Albrecht, J. and Odendahl, M. and Schlott, F. and Doessinger, G. and Schiemann, M. and Lakshmipathi, S. and Martin, K. and Bunjes, D. and Harsdorf, S. and Weissinger, E. M. and Menzel, H. and Verbeek, M. and Uharek, L. and Kroeger, N. and Wagner, E. and Kobbe, G. and Schroeder, T. and Schmitt, M. and Held, G. and Herr, W. and Germeroth, L. and Bonig, H. and Tonn, T. and Einsele, H. and Busch, D. H. and Grigoleit, G. U. (2017) Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. LEUKEMIA, 31 (10). pp. 2161-2171. ISSN 0887-6924, 1476-5551

Mielke, S. and Lutz, M. and Schmidhuber, J. and Kapp, M. and Ditz, D. and Ammer, J. and Einsele, H. and Grigoleit, G. U. and Holler, E. and Wolff, D. (2014) Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. BONE MARROW TRANSPLANTATION, 49 (11). pp. 1412-1418. ISSN 0268-3369, 1476-5365

Goekbuget, N. and Topp, M. S. and Zugmaier, G. and Viardot, A. and Stelljes, M. and Neumann, S. and Horst, H. and Reichle, A. and Marks, R. and Brueggemann, M. and Ritgen, M. and Klappers, P. and Mergen, N. and Goebeler, M. E. and Einsele, H. and Hoelzer, D. and Bargou, R. (2012) ANTI-CD19 BITE BLINATUMOMAB INDUCES HIGH COMPLETE REMISSION RATE IN ADULT PATIENTS WITH RELAPSED B-PRECURSOR ALL: UPDATED RESULTS OF AN ONGOING PHASE II TRIAL. ANNALS OF ONCOLOGY, 23 (Suppl1). i20-i21. ISSN 0923-7534

Topp, M. and Goekbuget, N. and Zugmaier, G. and Viardot, A. and Stelljes, M. and Neumann, S. and Horst, H-A and Reichle, A. and Marks, R. and Brueggemann, M. and Ritgen, M. and Klappers, P. and Mergen, N. and Goebeler, M-E and Einsele, H. and Hoelzer, D. and Bargou, R. (2012) Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor ALL. ONKOLOGIE, 35 (suppl6). p. 186. ISSN 0378-584X

Topp, M. S. and Goekbuget, N. and Zugmaier, G. and Viardot, A. and Stelljes, M. and Neumann, S. and Horst, H. -A and Reichle, A. and Marks, R. and Klappers, P. and Mergen, N. and Nagorsen, D. and Kufer, P. and Goebeler, M. -E and Einsele, H. and Hoelzer, D. and Bargou, R. (2011) Clinical activity of the anti-CD19 bite (R) blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase II study. ONKOLOGIE, 34 (Suppl6). p. 16. ISSN 0378-584X

Grube, M. and Loeffler, J. and Mezger, M. and Krueger, B. and Echtenacher, B. and Hoffmann, P. and Edinger, M. and Einsele, H. and Andreesen, R. and Holler, E. (2011) TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. BONE MARROW TRANSPLANTATION, 46 (Suppl1). S24-S25. ISSN 0268-3369, 1476-5365

Knop, S. and Liebisch, P. and Hebart, H. and Holler, E. and Engelhardt, M. and Bargou, R. C. and Metzner, B. and Doelken, G. and Peest, D. and Aulitzky, W. and Bunjes, D. and Straka, C. and Wandt, H. and Sezer, O. and Hentrich, M. and Ostermann, H. and Dechow, T. and Hess, G. and Hertenstein, B. and Freund, M. and Kropff, M. and Wolf, H. and Jung, W. and Frickhofen, N. and Maschmeyer, G. and Mergenthaler, H. and Kanz, L. and Meisner, C. and Einsele, H. (2011) Up front allogeneic stem cell transplant is superior to tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma. ONKOLOGIE, 34 (Suppl6). pp. 199-200. ISSN 0378-584X

Hilgendorf, I. and Jilg, W. and Einsele, H. and Greinix, H. and Halter, J. and Freund, M. and Lawitschka, A. and Wolff, D. and Meisel, R. (2010) Vaccination of haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. ONKOLOGIE, 33 (Suppl6). p. 28. ISSN 0378-584X

Schmidt-Hieber, M. and Blau, I. W. and Trenschel, R. and Andreesen, R. and Stuhler, G. and Einsele, H. and Kanz, L. and Keilholz, U. and Marinets, O. and Beelen, D. W. and Fauser, A. A. and Volin, L. and Ruutu, T. and Uharek, L. and Fietz, T. and Knauf, W. and Hopfenmueller, W. and Thiel, E. and Freund, M. and Casper, J. (2007) Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. BONE MARROW TRANSPLANTATION, 39 (7). pp. 389-396. ISSN 0268-3369

Knop, S. and Hebart, H. and Gratwohl, A. and Kliem, C. and Faul, C. and Holler, E. and Apperley, J. and Kolb, H. J. and Schaefer, A. and Niederwieser, D. and Einsele, H. (2007) Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. LEUKEMIA, 21 (8). pp. 1830-1833. ISSN 0887-6924

Schmidt-Hieber, M. and Casper, J. and Trenschel, R. and Andreesen, R. and Einsele, H. and Kanz, L. and Fauser, A. and Uharek, L. and Thiel, E. and Blau, I. (2006) Reduced-intensity conditioning with treosulfan and fludarabine prior to allogeneic stem cell transplantation in multiple myeloma patients. BONE MARROW TRANSPLANTATION, 37 (Suppl1). S195-S196. ISSN 0268-3369

Reich, G. and Cornely, O. A. and Sandherr, M. and Kubin, T. and Krause, Stefan and Einsele, H. and Thiel, E. and Bellaire, T. and Dorken, B. and Maschmeyer, Georg (2005) Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. BRITISH JOURNAL OF HAEMATOLOGY, 130 (2). pp. 265-270. ISSN 0007-1048, 1365-2141

Knop, S. and Hebart, H. and Gscheidle, H. and Holler, Ernst and Kolb, H. J. and Niederwieser, D. and Einsele, H. (2005) OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. BONE MARROW TRANSPLANTATION, 36 (9). pp. 831-837. ISSN 0268-3369

Conference or Workshop Item

Edinger, M. and Mackensen, A. and Einsele, H. and Herr, W. (2023) Collaborative Research Centre/Transregio 221: modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 13. bis 16. Oktober 2023, Hamburg, Germany.

Lüke, F. and Haller, F. and Spoerl, S. and Gerhard-Hartmann, E. and Utpatel, K. and Kunzmann, V and Chatterjee, M. and Maatouk, I and Bittrich, M. and Einwag, T. and Meidenbauer, N. and Hirsch, D. and Dietmaier, W. and Keil, F. and Scheiter, A. and Immel, A. and Heudobler, D. and Einhell, S. and Kaiser, U. and Maurer, J. and Herrmann, A. and Schenkirsch, G. and Sommer, S. and Jordan, F. and Dintner, S. and Rosenwald, A. and Hartmann, A. and Evert, M. and Maerkl, B. and Bargou, R. and Einsele, H. and Mackensen, A. and Beckmann, M. W. and Pukrop, T. and Herr, W. and Trepel, M. and Goebeler, M.-E. and Claus, R. and Kerscher, A. and Krebs, M. (2023) Screening and measuring patient access to precision oncology in a rural area of Germany - strategic toolbox of the WERA Cancer Center Network. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 13. bis 16. Oktober 2023, Hamburg, Germany.

Lüke, Florian and Haller, F. and Utpatel, K. and Krebs, M. and Meidenbauer, N. and Scheiter, A. and Spörl, S. and Heudobler, Daniel and Keil, F. and Schubart, C. and Tögel, L. and Einhell, S. and Dietmaier, W. and Huss, R. and Dintner, S. and Sommer, S. and Jordan, F. and Goebeler, M. E. and Metz, M. and Haake, D. and Scheytt, M. and Gerhard-Hartmann, E. and Maurus, K. and Braendlein, S. and Rosenwald, A. and Hartmann, A. and Märkl, B. and Einsele, H. and Mackensen, A. and Herr, Wolfgang and Kunzmann, V. and Bargou, R. and Beckmann, M. and Pukrop, Tobias and Trepel, M. and Evert, M. and Claus, R. and Kerscher, A. (2022) Recording of the regional Origin Areas of Patients from the Molecular Tumor Board to Identify the "white Spots" in the Service Area - A joint Initiative of the Bavarian CCC WERA Alliance. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien.

Other

Roellig, C. and Serve, H. and Huettmann, A. and Noppeney, R. and Mueller-Tidow, C. and Krug, U. and Baldus, C. D. and Brandts, C. H. and Kunzmann, V and Einsele, H. and Kraemer, A. and Schaefer-Eckart, K. and Neubauer, A. and Burchert, A. and Giagounidis, A. and Krause, S. W. and Mackensen, A. and Aulitzky, W. and Herbst, R. and Haenel, M. and Kiani, A. and Frickhofen, N. and Kullmer, J. and Kaiser, U. and Link, H. and Geer, T. and Reichle, A. and Junghanss, C. and Bornhaeuser, M. and Schaich, M. and Thiede, C. and Schetelig, J. and Kramer, M. and Berdel, W. E. and Ehninger, G. (2018) The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled SORAML trial. KARGER, BASEL.

Knop, S. and Langer, C. and Engelhardt, M. and Stuebig, T. and Schreder, M. and Dechow, T. and Muegge, L. -O. and Bassermann, F. and Schaefer-Eckart, K. and Blau, I. -W. and Wolleschak, D. and Kropff, M. and Reichle, A. and von Metzler, I. and Metzner, B. and Roellig, C. and Hertenstein, B. and Pfreundschuh, M. and Duerk, H. and Biersack, H. and Ostermann, H. and Menzel, H. and Schleicher, J. and Gramatzki, M. and Gerecke, C. and Mueller, M. and Brueggemann, M. and Held, S. and Einsele, H. (2017) Lenalidomide, adriamycin and dexamethasone (RAD) versus bortezomib, lenalidomide and dexamethasone (VRD) as induction regimens in newly diagnosed multiple myeloma - first results from the DSMM XIV study. KARGER, BASEL.

Jetani, H. and Garcia-Cadenas, I. and Nerreter, T. and Sierra, J. and Herr, W. and Thomas, S. and Einsele, H. and Hudecek, M. (2017) TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR T CELLS CONFERS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA. FERRATA STORTI FOUNDATION, PAVIA.

Schreder, M. and Liebisch, P. and Hebart, H. and Holler, E. and Engelhardt, M. and Metzner, B. and Peest, D. and Aulitzky, W. and Straka, C. and Fischer, T. and Sezer, O. and Hentrich, M. and Ostermann, H. and Peschel, C. and Hess, G. and Hertenstein, B. and Wolf, H. -H and Jung, W. and Frickhofen, N. and Maschmeyer, G. and Langer, C. and Meisner, C. and Kanz, L. and Einsele, H. and Knop, S. (2016) Randomized comparison of pegylated IFN-a2b versus IFN-a2b maintenance following tandem autologous transplant in multiple myeloma. KARGER, BASEL.

Einsele, H. and Vogel, M. and Mueller, J. and Knop, S. and Kropff, M. and Langer, C. and Sayer, H. and Jung, W. and Wandt, H. and Bassermann, F. and Gramatzki, M. and Roesler, W. and Brugger, W. and Engelhardt, M. and Fischer, T. and Giagounidis, A. and Heidemann, E. and Kroeger, N. and Sezer, O. and Bentz, M. and Pfreundschuh, M. and Salwender, H. and Ludwig, W. -D. and Roellig, C. and Staib, P. and Runde, V. and Scheid, C. and Ostermann, H. and Hess, G. and Hebart, H. and Repp, R. and Hart, C. and Frickhofen, N. and Straka, C. and Pflueger, K. -H. (2015) RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). FERRATA STORTI FOUNDATION, PAVIA.

Topp, M. S. and Goebeler, M-E and Einsele, H. and Bargou, R. and Goekbuget, N. and Zugmaier, G. and Mergen, N. and Klappers, P. and Viardot, A. and Stelljes, M. and Neumann, S. and Horst, H. A. and Bruegge-mann, M. and Ritgen, M. and Reichle, A. and Marks, R. and Faul, C. (2013) ANTI-CD19 BITE (R) BLINATUMOMAB INDUCES HIGH COMPLETE REMISSION RATE AND LONG OVERALL SURVIVAL IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ALL. SPRINGER, NEW YORK.

Topp, M. and Goekbuget, N. and Zugmaier, G. and Viardot, A. and Stelljes, M. and Neumann, S. and Horst, H. A. and Reichle, A. and Marks, R. and Faul, C. and Brueggemann, M. and Ritgen, M. and Klappers, P. and Mergen, N. and Goebeler, M. -E. and Einsele, H. and Hoelzer, D. and Bargou, R. (2013) Anti-CD19 BiTE (R) blinatumomab induces high complete remission rates in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia (ALL) including relapse after stem cell transplantation (SCT). NATURE PUBLISHING GROUP, LONDON.

Saussele, S. and Stein, M. and Gil, A. and Kossak-Roth, U. and Lauseker, M. and Hanfstein, B. and Proetel, U. and Schreiber, A. and Einsele, H. and Bokemeyer, C. and Schubert, J. and Haenel, M. and Spiekermann, K. and Soekler, M. and Nerl, C. and Kremers, S. and Pfreundschuh, M. and Andreesen, R. and Hofmann, W. and Hehlmann, R. and Hochhaus, A. and Hasford, J. and Grat-Wohl, A. and Mueller, M. and Pfirrmann, M. (2013) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: RESULTS OF A GERMAN CROSS-SECTIONAL STUDY IN PATIENTS PREVIOUSLY REGISTERED IN PROSPECTIVE, CONTROLLED CLINICAL TRIALS. FERRATA STORTI FOUNDATION, PAVIA.

Saussele, S. and Stein, M. and Gil, A. and Kossak-Roth, U. and Lauseker, M. and Hanfstein, B. and Proetel, U. and Schreiber, A. and Einsele, H. and Schafhausen, P. and Schubert, J. and Haenel, M. and Spiekermann, K. and Soekler, M. and Nerl, C. and Kremers, S. and Pfreundschuh, M. and Andreesen, R. and Hofmann, W-K and Hehlmann, R. and Hochhaus, A. and Hasford, J. and Gratwohl, A. and Mueller, M. C. and Pfirrmann, M. (2013) Health-related quality of life in patients with chronic myeloid leukemia: Results of a German cross-sectional study in patients previously registered in prospective, controlled clinical trials. KARGER, BASEL.

Knop, S. and Langer, C. and Engelhardt, M. and Muegge, L-O and Roesler, W. and Reichle, A. and Roellig, C. and Hertenstein, B. and Gramatzki, M. and Bassermann, F. and Ostermann, H. and Sturm, I and Ringhoffer, M. and Schaefer-Eckart, K. and Falk, K. and Liebert, A. and Einsele, H. and Bargou, R. (2013) Lenalidomide, Adriamycin, Dexamethasone (RAD) followed by risk-adjusted transplant is a novel and very effective induction regimen in newly diagnosed multiple myeloma. KARGER, BASEL.